simeprevir

This page shows the latest simeprevir news and features for those working in and with pharma, biotech and healthcare.

Remicade safe from biosimilar competition this year, says J&J

On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in

Latest news

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
J&J's share buyback 'doesn't prevent acquisitions'

disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products.
J&J starts to feel biosimilar competition bite

toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
J&J signs $1bn deal with Achillion for hepatitis C therapies

J&J already has one new-generation oral HCV therapy on the market, its NS3/4A protease inhibitor Olysio (simeprevir), but could do with additional drugs in its portfolio in order
Harvoni sales rocket in first quarter

simeprevir), while Merck &Co also has a new treatment in the works.

More from news
Approximately 9 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Taking a strategic approach

Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Medivir names new CEO

simeprevir). “Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Warehousing of HCV patients reaches new high

Gilead’s interferon-free product sofosbuvir and Johnson &Johnson’s simeprevir appear to lead the field – receiving the highest levels of spontaneous and prompted awareness. ... However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Healthcare Marketing Agency: Salary TBC

Project Manager/ Account Manager: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Up to £50, 000 with Benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer: Great salary and benefits

Digital Account Director: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Director, Medical Education: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...